钾离子竞争性酸阻滞剂二联疗法根除幽门螺杆菌的改良与探索  

Improvement and exploration of potassium⁃competitive acid blockers dual therapy for the eradication of Helicobacter pylori

作　　者：陈威威 彭若琳 瞿燚 张振玉[1] CHEN Weiwei;PENG Ruolin;QU Yi;ZHANG Zhenyu(Department of Gastroenterology,Nanjing First Hospital,Nanjing Medical University,Nanjing 210006,Jiangsu,China)

机构地区：[1]南京医科大学附属南京医院(南京市第一医院)消化内科,江苏南京210006

出　　处：《实用医学杂志》2024年第19期2806-2812,共7页The Journal of Practical Medicine

基　　金：南京市卫生科技发展项目(编号:YKK22116)。

摘　　要：幽门螺杆菌感染是萎缩性胃炎、消化性溃疡和胃癌等多种胃肠道疾病的重要致病因素。及时的根除治疗有利于维护患者健康。随着幽门螺杆菌耐药性增加,质子泵抑制剂联合大剂量阿莫西林的二联疗法逐渐得到重视。钾离子竞争性酸阻滞剂是一类新型抑酸剂,相比传统的质子泵抑制剂,其起效更快,抑酸作用更持久,更加适用于二联疗法。近年来,学者们对钾离子竞争性酸阻滞剂二联疗法进行了大量探索、改良及验证,现对其研究进展进行综述。Helicobacter pylori infection is an important causative factor in a variety of gastrointestinal diseases,such as atrophic gastritis,peptic ulcer disease,and gastric cancer.Timely eradication treatment is con-ducive to maintaining the health of patients.With the increase of drug resistance in Helicobacter pylori,dual therapy with proton pump inhibitors combined with high-dose amoxicillin has gradually gained attention.Potassium-competitive acid blockers are new types of antacids that have a faster onset of action and a longer lasting acid sup-pression effect than traditional proton pump inhibitors,making it more suitable for dual therapy.In recent years,scholars have carried out a lot of exploration,improvement and verification of potassium-competitive acid blockers dual therapy,and this article reviews its research progress.

关 键 词：幽门螺杆菌 钾离子竞争性酸阻滞剂 阿莫西林 二联疗法 

分 类 号：R978.1[医药卫生—药品]